NASDAQ:CRVSCorvus Pharmaceuticals Stock Price, Forecast & News

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRVS shares have increased by 20.1% and is now trading at $3.2550. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corvus Pharmaceuticals.

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Corvus Pharmaceuticals.

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) released its quarterly earnings data on Thursday, April, 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.04. View Corvus Pharmaceuticals' earnings history.

3 brokers have issued 12-month target prices for Corvus Pharmaceuticals' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Corvus Pharmaceuticals' share price to reach $8.33 in the next twelve months. This suggests a possible upside of 156.0% from the stock's current price. View analysts' price targets for Corvus Pharmaceuticals.

Headlines about CRVS stock have been trending very negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutCorvus Pharmaceuticals.

Some companies that are related to Corvus Pharmaceuticals include MEI Pharma (MEIP), XBiotech (XBIT), Albireo Pharma (ALBO), Axovant Sciences (AXON), Ocular Therapeutix (OCUL), Progenics Pharmaceuticals (PGNX), CytomX Therapeutics (CTMX), Magenta Therapeutics (MGTA), Humanigen (HGEN), Calithera Biosciences (CALA), ANI Pharmaceuticals (ANIP), Avid Bioservices (CDMO), Kamada (KMDA), Seres Therapeutics (MCRB) and Spectrum Pharmaceuticals (SPPI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD), ImmunoGen (IMGN) and Immunomedics (IMMU).

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (0.36%), Connor Clark & Lunn Investment Management Ltd. (0.31%), Hikari Power Ltd (0.22%), Morgan Stanley (0.12%), Russell Investments Group Ltd. (0.11%) and Two Sigma Advisers LP (0.10%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View institutional ownership trends for Corvus Pharmaceuticals.

CRVS stock was sold by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Two Sigma Investments LP, and Morgan Stanley. View insider buying and selling activity for Corvus Pharmaceuticals.

CRVS stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, Two Sigma Advisers LP, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller. View insider buying and selling activity for Corvus Pharmaceuticals.

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRVS stock can currently be purchased for approximately $3.26.

Corvus Pharmaceuticals has a market capitalization of $90.99 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Corvus Pharmaceuticals employs 49 workers across the globe.

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]